← Back to patent-cliff list
Ganaplacide/Lumefantrine
Tier C — Watch / tradeGanaplacide/Lumefantrine
Novartis
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Hemozoin, PI4K
Indications (approved)：Falciparum malaria, Plasmodium infection
Regional status
US
-
EU
Phase I
2021-11-18
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ganaplacide/Lumefantrine?
Approved indications include: Falciparum malaria, Plasmodium infection.
When does the Ganaplacide/Lumefantrine patent expire?
No public expiry year is available for Ganaplacide/Lumefantrine yet; this page updates once verified.
How do I get a quote for Ganaplacide/Lumefantrine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01